Related Experiment Videos
[Prevention of neonatal apnea with theophylline (author's transl)]
Insights
Theophylline effectively reduces apnea frequency in premature infants. This treatment is a safe addition to existing therapies, with minimal side effects observed.
Area of Science:
- Neonatal Medicine
- Pharmacology
Context:
- Neonatal apnea is a common concern in premature infants.
- Established treatments include stimulation, CPAP, and mechanical ventilation.
Purpose:
- To evaluate the efficacy and safety of theophylline as a treatment for neonatal apnea.
Summary:
- Theophylline therapy was administered to 10 premature infants with apnea.
- An initial dose of 6 mg/kg followed by 2 mg/kg every 12 hours significantly reduced apnea frequency.
- Minor side effects, such as transient tachycardia, were observed in only two infants.
Impact:
- Theophylline offers a new therapeutic option for managing neonatal apnea.
- It demonstrates a favorable safety profile, reducing the need for additional interventions.
Abstract:
To the well known methods for prevention of neonatal apnea like stimulation, CPAP, and mechanical ventilation the treatment with theophylline has been added recently. We studied the efficiency of theophylline therapy in 10 premature infants with apnea. The initial dosage was 6 mg theophylline/kg body-weight, followed by a dosage of 2 mg/kg for the next 12 h. The frequency of apnea thereby was significantly reduced. Only in two cases the heart rate rose above 180/min as a side effect. In no case an additional therapy was necessary.